

Press Release



EQT agrees to sale of shares in Galderma Group AG to L'Oréal S.A.

- C. 24 million shares to be sold

Further to previous announcements, an affiliate of the funds known as EQT VIII ("**EQT**") is pleased to announce it has signed an agreement to sell c. 24 million shares in Galderma Group AG (SIX: GALD) (the "**Company**") to L'Oréal S.A at an undisclosed premium (the "**Sale**"). Out of the total shares to be sold, c. 6 million are attributable to EQT.

The closing of the Sale is subject to customary regulatory approvals.

Contact

EQT Press Office, press@eqtpartners.com

Important notice

This press release does not constitute (i) an offer to sell or a solicitation of an offer to buy any securities of Galderma Group AG or any of its affiliates and it does not constitute a prospectus within the meaning of the Swiss Financial Services Act or (ii) an offer of securities for sale in the United States or elsewhere. Securities may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration. There will be no public offering of any of the securities mentioned in this press release in the United States.

About EQT

EQT is a purpose-driven global investment organization with €267 billion in total assets under management (€139 billion in fee-generating assets under management) as of 30 September 2025, within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com

Follow EQT on [LinkedIn](#), [X](#), [YouTube](#) and [Instagram](#)

About Galderma Group AG

Galderma Group AG is a pure-play leader in the dermatology category, with a presence in approximately 90 countries. It delivers an innovative, science-based portfolio of premium flagship brands and services that cover the full spectrum of the rapidly growing dermatology market. This includes Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since its foundation in 1981, Galderma has dedicated its focus and passion to the human body's largest organ – the skin – addressing individual consumer and patient needs with superior outcomes in collaboration with healthcare professionals.